cemiplimab (Libtayo®)
Application Details
HSE100124
26036a
cemiplimab
Libtayo®
Regeneron Ireland Designated Activity Company (DAC)
14/07/2026
21/06/2021
Application Status
Rapid Review Completed
14/08/2026
Pricing and Reimbursement Application Complete
14/07/2026
Rapid Review Commissioned
10/07/2026